Connections Eisai Co., Ltd.

Stocks

4523

JP3160400002

Pharmaceuticals

Delayed Japan Exchange 07:35:32 15/06/2026 am IST 5-day change 1st Jan Change
3,790.00 JPY +0.26% Intraday chart for Eisai Co., Ltd. -0.24% -18.52%

28

Listed companies

9

Private companies

112

Insiders

Relation chart of related listed companies: Eisai Co., Ltd.

Active Relations

Past Relations

Relationship chart for related private companies: Eisai Co., Ltd.

Active Relations

Past Relations

Related private companies: Eisai Co., Ltd.

Eisai Ltd. (United Kingdom)

Pharmaceuticals: Major

Meiji University

Other Consumer Services

Sunplanet Co., Ltd.

Miscellaneous Commercial Services

EA Pharma Co., Ltd.

Pharmaceuticals: Major

Eisai Farmacéutica SA

Pharmaceuticals: Major

H3 Biomedicine, Inc.

Miscellaneous Commercial Services

Eisai China, Inc.

Pharmaceuticals: Major

Eisai Manufacturing Ltd.

Pharmaceuticals: Major

Eisai Europe Ltd.

Pharmaceuticals: Major

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Pharmaceuticals: Major10
Miscellaneous Commercial Services2
Information Technology Services2
Auto Parts: OEM2
Biotechnology2
Regional Banks2
Advertising/Marketing Services1
Other Consumer Services1
Internet Retail1
Electronic Production Equipment1

Countries of related companies

Japan26
United States4
United Kingdom3
Denmark2
China1
Spain1
Logo Eisai Co., Ltd.
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Employees
10,917
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!